PROGNOSTIC VALUE OF N-MYC GENE AMPLIFICATION IN PATIENTS WITH NEUROBLASTOMA

Abstract

This work presents the results of studying the prognostic value of the N-MYC gene amplification in patients with neuroblastoma treated according to the European protocol NB-2004. A retrospective analysis of 140 patients who were diagnosed with neuroblastoma from 2013-2019 was carried out at the SCP and PS. When collecting data from 140 patients with neuroblastoma, amplification of the N-MYC gene was found in 26 patients, of which 19 patients died (73%), 7 patients are alive (survival rate -27%). Amplification of the NMYC gene occurred with the same frequency in boys and girls, 50% in each group. In children under one year old, there were 6 children (23.1%), 1-2 years old 12 patients (46.2%), 2-5 years old 5 children (19.2%), over 5 years old 3 patients (11.5%). In 13 (50%) children, the primary tumor was localized in the adrenal glands, in 11 (42%) - in the retroperitoneal space and in 2 (7.7%) in the mediastinum. In 21 (80.8%) patients with amplification of the N-MYC gene, the disease was diagnosed at stage IV, in 2 cases (7.7%) with stage IVs, and 1 (3.8%) case at I, II, III stage of the disease. Thus, patients with N-MYC gene amplification were more often detected at stage IV of the disease and had an unfavorable outcome.The fact of the negative impact of amplification of the N-MYC gene is confirmed in our study. The therapeutic protocol is ineffective in the presence of N-MYC gene amplification (survival - 27%). Keywords: Neuroblastoma, NMYC gene amplification, prognosis, children.